The year 2024 was momentous for metabolic dysfunction-associated steatotic liver disease (MASLD): the approval of the first medication for treatment of at-risk metabolic dysfunction-associated steatohepatitis, updated guidelines on the screening, diagnosis and treatment of MASLD, and liver stiffness measurement as an important surrogate marker for liver-related outcomes in MASLD.

中文翻译：

---

MASLD 的新治疗方法和更新的临床实践指南


2024 年对于代谢功能障碍相关脂肪性肝病 （MASLD） 来说是重要的一年：第一种治疗高危代谢功能障碍相关脂肪性肝炎的药物获得批准，更新了 MASLD 筛查、诊断和治疗的指南，以及肝脏硬度测量作为 MASLD 肝脏相关结果的重要替代标志物。